X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Retevmo (selpercatinib) is an oral RET receptor tyrosine kinase inhibitor, small molecule drug candidate which is indicated for the treatment of RET fusion-positive solid tumors.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity, which is investigated for the treatment of advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity, which is used for the treatment of Adults with Newly-Diagnosed Advanced or Metastatic RET fusion-positive non-small Cell lung cancer.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2023
Details:
Selpercatinib is selective and potent RET kinase inhibitor demonstrated potent and durable antitumor activity with favorable safety profile in patients with advanced or metastatic RET fusion-positive NSCLC, metastatic RET-mutant MTC and advanced RET fusion-positive TC.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
In the LIBRETTO-001 trial, Retevmo (selpercatinib) demonstrated clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers, including pancreatic, colon and other cancers in need of new treatment options.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Twenty-six patients had measurable central nervous system metastases at baseline and treatment with Retevmo resulted in a CNS ORR of 84.6%, with 22 patients having a confirmed best response of complete response or partial response.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
First-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising antitumour activity and safety in various RET fusion-positive advanced solid tumours. Safety consistent with known profile of Retevmo.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retevmo
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Loxo Oncology Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2021
Details:
The agency approved selpercatinib for the treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Retsevmo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
Retevmo™ (selpercatinib) has been approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
The NDA is based on data from the LIBRETTO-001 Phase 1/2 trial in RET-altered lung and thyroid cancers.
Lead Product(s): Selpercatinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
